Coeurative, Inc. is working to ensure that every heartbeat matters.
Millions of patients suffer from a syndrome known as angina pectoris, symptoms that signal that the heart is not getting the oxygen-rich blood that it needs to function.
Coeurative is harnessing a cellular response to a deficiency in blood and oxygen that can open a coronary artery more effectively and more selectively than currently available vasodilators. We are pioneering a fundamentally different approach to coronary artery disease to restore proper blood flow and reclaim cardiovascular health.
Coeurative aims to bring relief to patients with angina pectoris, with a focus on the patients that suffer from INOCA (Ischemia with Non-Obstructive Coronary Arteries) and refractory angina pectoris.
This is more than pharmaceutical development. This is a commitment to transforming how we treat heart disease and giving patients their lives back, one restored heart at a time.
First-in-Class Innovation
CR-0305 has the potential to deliver both immediate relief and long-term vascular benefits through proprietary dual-mechanism approach
23× more potent than current standard-of-care treatments in ex vivo studies with favorable safety profile
IND-enabling studies underway with Phase 1 trials planned for 2027
Market Opportunity
10+ million Americans living with angina pectoris
21% still experience monthly attacks despite medical therapy
$15B+ global market opportunity by 2029
3-17% annual mortality rate in refractory patients
Click here to link to an introductory slide deck describing Coeurative, Inc. and its lead compound.
Coeurative, Inc. 